Antibodies against immature virions are not a discriminating factor for dengue disease severity

PLoS Neglected Tropical Diseases
Izabela A Rodenhuis-ZybertJolanda M Smit

Abstract

Humoral immunity plays an important role in controlling dengue virus (DENV) infection. Antibodies (Abs) developed during primary infection protect against subsequent infection with the same dengue serotype, but can enhance disease following secondary infection with a heterologous serotype. A DENV virion has two surface proteins, envelope protein E and (pre)-membrane protein (pr)M, and inefficient cleavage of the prM protein during maturation of progeny virions leads to the secretion of immature and partially immature particles. Interestingly, we and others found that historically regarded non-infectious prM-containing DENV particles can become highly infectious in the presence of E- and prM-Abs. Accordingly, we hypothesized that these virions contribute to the exacerbation of disease during secondary infection. Here, we tested this hypothesis and investigated the ability of acute sera of 30 DENV2-infected patients with different grades of disease severity, to bind, neutralize and/or enhance immature DENV2. We found that a significant fraction of serum Abs bind to the prM protein and to immature virions, but we observed no significant difference between the disease severity groups. Furthermore, functional analysis of the Abs did...Continue Reading

References

Jul 1, 1977·The Journal of Experimental Medicine·S B Halstead, E J O'Rourke
Jul 1, 1990·Memórias do Instituto Oswaldo Cruz·R J Fernández, S Vázquez
Apr 1, 1989·The American Journal of Tropical Medicine and Hygiene·S C KliksD S Burke
Dec 23, 1999·The Journal of Infectious Diseases·D W VaughnA Nisalak
Sep 6, 2000·Clinical and Diagnostic Laboratory Immunology·K ValdésM G Guzmán
May 19, 2001·The American Journal of Tropical Medicine and Hygiene·E HarrisA Balmaseda
Feb 14, 2003·Journal of Virology·Xinyong ZhangMargaret Kielian
May 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yorgo ModisStephen C Harrison
Sep 3, 2004·Structure·Ying ZhangMichael G Rossmann
Jan 21, 2006·The Journal of Infectious Diseases·Donald S Burke, Srisakul Kliks
Feb 24, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kao-Jean HuangHuan-Yao Lei
Jun 15, 2006·Tropical Medicine & International Health : TM & IH·Angel BalmasedaEva Harris
Sep 22, 2006·Journal of Virology·Grant E NybakkenDaved H Fremont
May 19, 2007·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Vanda Akico Ueda Fick de SouzaCláudio Sérgio Pannuti
Nov 13, 2007·Lancet·Scott B Halstead
May 10, 2008·PLoS Pathogens·Steevenson NelsonTheodore C Pierson
Nov 15, 2008·The Journal of General Virology·Izabela A ZybertJolanda M Smit
Oct 14, 2009·Clinical Microbiology Reviews·Byron E E MartinaAlbert D M E Osterhaus
Jan 12, 2010·PLoS Pathogens·Izabela A Rodenhuis-ZybertJolanda M Smit
Apr 8, 2010·Cellular and Molecular Life Sciences : CMLS·Izabela A Rodenhuis-ZybertJolanda M Smit
May 8, 2010·Science·Wanwisa DejnirattisaiGavin Screaton
Mar 11, 2011·Trends in Microbiology·Izabela A Rodenhuis-ZybertJolanda M Smit
Jun 30, 2011·PLoS Neglected Tropical Diseases·Ruklanthi de AlwisAravinda M de Silva
Sep 2, 2011·Journal of Virology·Izabela A Rodenhuis-ZybertJolanda M Smit
Nov 17, 2011·PLoS Neglected Tropical Diseases·Federico NarvaezEva Harris
Mar 27, 2012·Current Opinion in Virology·Theodore C Pierson, Michael S Diamond
Apr 14, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ruklanthi de AlwisAravinda M de Silva
Apr 9, 2013·Nature·Samir BhattSimon I Hay

❮ Previous
Next ❯

Citations

Jul 18, 2019·Human Vaccines & Immunotherapeutics·Jedhan Ucat GalulaDay-Yu Chao
Jun 13, 2015·PLoS Neglected Tropical Diseases·Jacky Flipse, Jolanda M Smit
Oct 11, 2017·Frontiers in Immunology·Denicar Lina Nascimento Fabris MaedaJuliana Falcão Rodrigues
Nov 19, 2015·Expert Review of Vaccines·Eliana G Acosta, Ralf Bartenschlager
Nov 13, 2015·Expert Review of Vaccines·Anon Srikiatkhachorn, In-Kyu Yoon
Jan 10, 2020·Cell Host & Microbe·Matthew G ZimmermanMehul S Suthar

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
ELISA
flow cytometry
glycosylation

Software Mentioned

ImageQuant
ImageQuant TL

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.